



# Bharat Parenterals Limited

**Registered Office & Works:**

Vill. Haripura, Ta. Savli, Dist. Vadodara - 391520 (Guj.) India.

Tele : (02667)-251679, 251680, 251669, 99099 28332.

E-mail: info@bplindia.in, Web.: www.bplindia.in

CIN NO: U24231GJ1992PLC018237

(WHO-GMP CERTIFIED ★ STAR EXPORT HOUSE)

To  
The Manager,  
Listing Department,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400001

Date: 14.11.2018

**SCRIP CODE: 541096**

Dear Sir,

**Sub.: Outcome of the Board Meeting**

With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Bharat Parenterals Limited at its meeting held today has approved the unaudited financial results for the quarter and six months ended on 30<sup>th</sup> September, 2018.

We enclose herewith Independent Auditor's Limited Review Report, Statement of Standalone Unaudited Financial Results for the quarter and half year ended on 30<sup>th</sup> September, 2018 along with Statement of Assets & Liabilities as on 30<sup>th</sup> September, 2018.

The Board meeting commenced on 16:00 hours (IST) and concluded at 17:00 hours (IST)

We request you to kindly take the above on record.

Yours Faithfully,

For Bharat Parenterals Limited

Monica Ahir

Company Secretary & Compliance Officer



Encl.: As stated above

**Corporate Office:**

Shree Avenue, 1st Floor, Above Bank of Baroda, Nr. Amit Nagar Circle, VIP Road, Karelibaug,  
Vadodara - 390 022 (Guj.) India. Ph.: (0265) - 3935232, 3935233, 3935234, 99099 84243

**BHARAT PARENTERALS LIMITED**

Regd. Office : Vill Haripura, TA Savli, District: Vadodara - 391 520

Corporate Office : Shree Avenue, 1st Floor, Above Bank of Baroda, Near Amit Nagar Circle, VIP Road, Karelibaug, Vadodara - 390 018

CIN:U24231GJ199ZPLC018237

Website: www.bplindia.in

**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS  
ENDED 30TH SEPTEMBER, 2018**

(Rs. in Lakhs)

Sr. No.	Particulars	Quarter Year Ended			Half Year Ended		Year Ended
		30.09.18	30.06.2018	30.09.17	30.09.18	30.09.17	31.03.2018
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	<b>A. Revenue from operations</b>	4,988.67	3,781.06	3,519.95	8,769.73	6,386.35	13,828.88
	<b>B. Other Income</b>	219.27	199.09	376.36	418.36	533.11	701.40
	<b>Total income</b>	<b>5,207.94</b>	<b>3,980.15</b>	<b>3,896.31</b>	<b>9,188.09</b>	<b>6,919.46</b>	<b>14,530.28</b>
2	<b>Expenses</b>						
	A. Cost of materials consumed	3,160.43	2,123.45	2,323.29	5,283.88	4,234.82	8,881.03
	B. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(414.16)	(8.03)	5.19	(422.19)	(124.53)	(82.52)
	C. Excise duty on sale of goods	-	-	-	-	196.02	196.02
	D. Employee benefit expense	397.51	399.04	217.86	796.55	387.92	1,236.76
	E. Finance costs	36.78	17.36	19.80	54.14	52.80	93.93
	F. Depreciation, depletion and amortisation expense	145.98	142.77	154.66	288.75	302.82	557.23
	G. Other Expenses	771.83	611.41	576.00	1,383.24	1,002.26	2,270.27
	<b>Total expenses</b>	<b>4,098.37</b>	<b>3,286.01</b>	<b>3,296.81</b>	<b>7,384.38</b>	<b>6,052.13</b>	<b>13,152.74</b>
3	<b>Total profit before tax</b>	<b>1,109.57</b>	<b>694.14</b>	<b>599.50</b>	<b>1,803.71</b>	<b>867.32</b>	<b>1,377.54</b>
4	<b>Tax expense</b>						
	Current tax	357.53	200.00	-	557.53	-	510.00
	Deferred tax	313.38	(36.33)	-	277.05	-	(142.44)
	<b>Total tax expenses</b>	<b>670.91</b>	<b>163.67</b>	<b>-</b>	<b>834.58</b>	<b>-</b>	<b>367.56</b>
5	<b>Net Profit / (loss) for period</b>	<b>438.66</b>	<b>530.47</b>	<b>599.50</b>	<b>969.14</b>	<b>867.32</b>	<b>1,009.99</b>
6	<b>Other comprehensive Income</b>						
	<b>Items that will not be reclassified to profit or loss</b>						
	Remeasurement of defined benefit obligation	1.85	1.85	-	3.70	-	7.41
	<b>Income tax relating to items that will not be reclassified to profit or loss</b>						
	Remeasurement of defined benefit obligation	(0.54)	(0.54)	-	(1.08)	-	(2.16)
	<b>Other comprehensive Income for the year, net of taxes</b>	<b>1.31</b>	<b>1.31</b>	<b>-</b>	<b>2.62</b>	<b>-</b>	<b>5.25</b>
7	<b>Total Comprehensive Income for the period</b>	<b>439.97</b>	<b>531.78</b>	<b>599.50</b>	<b>971.75</b>	<b>867.32</b>	<b>1,015.24</b>
8	<b>Earnings per share</b>						
	Basic (Rs.)	7.66	9.26	10.46	16.91	15.14	17.63
	Diluted (Rs.)	7.66	9.26	10.46	16.91	15.14	17.63

See accompanying notes to the Financial Results

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- The Company has only one segment of activity, namely "Pharmaceuticals."
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

For Bharat Parenterals Limited



Bharat R. Desai  
Managing Director

Place : Vadodara

Date : 14<sup>th</sup> November, 2018



## BHARAT PARENTERALS LIMITED

Regd. Office : Vill Haripura, TA Savli, District: Vadodara - 391520

Corporate Office : Shree Avenue, 1st Floor, Above Bank of Baroda, Near Amit Nagar Circle, VIP.

CIN:U24231GJ199ZPLC018237

### STATEMENT OF STANDALONE ASSETS AND LIABILITIES AS AT 30<sup>TH</sup> SEPTEMBER, 2018

Sr. No.	Particulars	As at 30th September,2018	As at 31st March,2018
		Unaudited	Audited
	<b>ASSETS</b>		
<b>I</b>	<b>Non current Assets</b>		
	(a) Property, Plant and Equipment	3,350.02	3,371.15
	(b) <u>Financial Assets</u>		
	(i) Investments	66.58	74.17
	(ii) Loans	115.29	45.77
	(iii) Other Financial assets	430.03	371.67
	(c) Deferred tax assets (net)	-	219.42
	(d) Other Non Current Assets	311.14	318.13
<b>II</b>	<b>Current assets</b>		
	(a) Inventories	2,434.71	1,442.89
	(b) <u>Financial Assets</u>		
	(ii) Trade receivables	4,738.72	5,892.24
	(iii) Cash and cash equivalents	851.78	387.83
	(iii) Other financial assets	21.74	29.31
	(c) Other current assets	2,445.42	1,184.46
	<b>Total Assets</b>	<b>14,765.44</b>	<b>13,337.06</b>
	<b>EQUITY AND LIABILITIES</b>		
<b>III</b>	<b>Equity</b>		
	(a) Equity Share capital	572.97	572.97
	(b) Other Equity	8,029.12	6,858.81
		<b>8,602.08</b>	<b>7,431.78</b>
	<b>LIABILITIES</b>		
	<b>Non-Current liabilities</b>		
<b>IV</b>	(a) <b>Financial Liabilities</b>		
	(i) Borrowings	43.80	233.77
	(b) Provisions	11.20	7.55
	(c) Deferred tax liabilities (net)	58.69	-
	<b>Current liabilities</b>		
<b>V</b>	(a) <u>Financial Liabilities</u>		
	(i) Borrowings	303.28	530.68
	(ii) Trade payables	2,849.51	2,647.70
	(iii) Other financial liabilities	278.30	157.51
	(b) Other current liabilities	2,334.96	2,052.34
	(c) Provisions	1.09	0.74
	(d) Current Tax Liabilities (Net)	282.53	275.00
	<b>Total Liabilities</b>	<b>6,163.36</b>	<b>5,905.29</b>
	<b>Total Equity and Liabilities</b>	<b>14,765.44</b>	<b>13,337.06</b>

For Bharat Parenterals Limited

  
**Bharat R. Desai**  
 Managing Director  
 Place : Vadodara  
 Date : 14<sup>th</sup> November, 2018



**Limited Review Report****To the Board of Directors of Bharat Parenterals Limited**

1. We have reviewed the accompanying statement of unaudited standalone Ind-AS financial results of **Bharat Parenterals Limited** ("the Company") for the quarter/half year ended 30<sup>th</sup> September, 2018 ("the Statement") together with the notes thereon attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which has been initialed by us for identification purposes.
2. This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
4. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone Ind-AS financial results has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For, CNK & Associates LLP**

Chartered Accountants

Firm Registration no. 101961W/W-100036

**Kishor Parikh**

(Partner)

Membership No. - 039213

Vadodara, 14<sup>th</sup> November, 2018